Category Archives: Stell Cell Research


Single-cell Analysis Market worth $6.3 billion by 2026 – Exclusive Report by MarketsandMarkets – GlobeNewswire

Chicago, Sept. 01, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instrument), Technique (Flow Cytometry, NGS, PCR, Microscopy, MS), Application (Research, Medical), End User (Pharma, Biotech, Hospitals) - Global Forecast to 2026", is projected to reach USD 6.3 billion by 2026 from USD 3.1 billion in 2021, at a CAGR of 15.1% during the forecast period.

Browse and in-depth TOC on "Single-cell Analysis Market" 257 - Tables 57 - Figures 296 Pages

List of Key Players in the Single-cell Analysis Market:

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

Single-Cell Analysis Market Dynamics:

Growth in this market is mainly driven by factors such as technological advancements in single-cell analysis products coupled with increasing R&D in the pharmaceutical and biotechnology industries, growing focus on personalized medicine, growth in stem cell research, and the rising prevalence of cancer. However, the high cost of single-cell analysis products is a major factor hampering the growth of the single-cell analysis market.

Based on products, the single-cell analysis market is segmented into consumables and instruments. Consumables accounted for the largest share of 67.4% of the single-cell analysis market in 2020. The large share of this segment can primarily be attributed to the frequent purchase of these products compared to instruments, which are considered a one-time investment. The wide applications of consumables in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are also expected to drive market growth.

Based on cell type, the single-cell analysis market is segmented into human cells, animal cells, and microbial cells. The human cells segment accounted for the largest share of 51.6% of the single-cell analysis market in 2020. The large share of this segment can be attributed to the high utilization of human cells in research laboratories and academic institutes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254

Based on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques. The flow cytometry segment accounted for the largest market share of 29.7% in 2020. The large share of this segment can be attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles.

Based on applications, the single-cell analysis market is segmented into research and medical applications. The research applications segment accounted for the largest share of 68.3% of the single-cell analysis market in 2020. Increasing government initiatives in stem cell research and the wide usage of single-cell analysis in cancer research are the major factors driving the growth of the research applications segment.

Based on end users, the single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. In 2020, the academic & research laboratories segment accounted for the largest share of the single-cell analysis market. Factors such as growth in funding for life science research and the increasing number of medical colleges and universities are driving the growth of this end-user segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=171955254

Geographical Growth Scenario:

Based on region, the single-cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of 44.9% of the global single-cell analysis market in 2020. This market is expected to reach USD 2,520.2 million by 2026 from an estimated USD 1,282.2 million in 2021, at a CAGR of 14.5%. North Americas prominence in this market is mainly attributed to the presence of key market players, coupled with increasing R&D expenditure and federal funding.

Browse Adjacent Markets:Biotechnology Market Research Reports & Consulting

Browse Related Reports:

Flow Cytometry Market by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End user (Biotech, Hospitals) - Global Forecast to 2027

Cell Analysis Market by Product & Service (Reagents & Consumables, Instruments), Technique (Flow Cytometry, High Content Screening), Process (Single-cell Analysis), End User (Pharmaceutical and Biotechnology Companies) - Global Forecast to 2027

Follow this link:
Single-cell Analysis Market worth $6.3 billion by 2026 - Exclusive Report by MarketsandMarkets - GlobeNewswire

Mayflower BioVentures to Announce New Cell & Gene Therapy Companies within Months – BioSpace

James R. Martin/Shutterstock

A cell and gene therapy accelerator formed by Mayo Clinic, Hibiscus BioVentures and Innoforce is officially up and running, the partners announced Wednesday.

Mayflower BioVentures will identify and launch companies around technologies that address unmet patient needs.

Mayo Clinic hasaccumulated a portfolio of next-generation immune system modulators as well as numerous novel therapeutics in cell and gene therapy. Now Mayo is sharing those discoveries and research capabilities in hopes of reaching patients.

We have the first right to look at the technologies that Mayo considered to be high-value opportunities, Chris Jeffers, CEO of Hibiscus BioTechnology, told BioSpace. Thats an internal designation. And we have the first rights to create companies from those.

It gives Hibiscus the opportunity to incubate and accelerate the companies within Mayflower anywhere between one and two years. Eventually our goal is to graduate those companies to be self-sufficient, independent companies that can obtain their own funding once they leave the accelerator, Jeffers added.

Andrew Danielsen, chair of Mayo Clinic Ventures, told BioSpace that each company will be within Mayflower and owned by the investor syndicate proportionally.

Mayflower has been in the works for at least a year, Jeffers and COO Sia Anaganostou shared, adding that they have been working with Mayo on identifying and developing several companies, which they expect to announce in the coming months.

While unable to provide further details, Jeffers said the areas of focus are anticipated to range from various types of stem cell therapies and gene therapies covering a number of conditions. Some of those technologies are ancillary to cellular therapies, while some are for new pathways to try to escape from traditional immuno-oncology, he said.

Mayflower will be run by the Hibiscus management team.

This is a big push from the Mayo Clinic to really increase its commercialization in this space. Were really proud to be associated with such a fantastic institution with unparalleled clinical expertise, Jeffers said, adding that these factors are a real differentiator.

Danielsen spoke of transitioning research from bench to bedside.

We believe this collaboration can bridge the gap between industry and innovative cell and gene therapy research, enabling emerging startups to navigate the challenges of producing meaningful, novel therapeutics that transform health and medicine, he said in a statement.

Mayos Center for Regenerative Biotherapeutics focuses on advancing regenerative technologies from discovery into early phase clinical studies.

Hibiscus is a venture capital firm focused on building patient-focused companies around new technology and helping to develop those discoveries into commercial drugs and therapies. Hibiscus is comprised of Hibiscus Biotechnology, a venture studio that works to build companies from scratch, and Hibiscus Capital Management, a VC firm that invests in promising early-stage biotech companies.

Innoforce is a partnership-focused biopharma company targeting advanced therapy medicinal products (ATMPs) and biologics. It offers contract development and manufacturing services including GMP manufacturing of plasmid DNA, RNA, viral vector and cell products.

Any revenue generated by Mayflower will go toward Mayo Clinics patient care, education and research.

Excerpt from:
Mayflower BioVentures to Announce New Cell & Gene Therapy Companies within Months - BioSpace

Applied StemCell expands manufacturing facility to support cell and gene therapies – BioPharma-Reporter.com

The Milpitas, California cell and gene therapy CRO/CDMO, whose focus is on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products, has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space.

The expansion of the facility will increase its cell banking and cell product manufacturing capacity and allow ASCs team of experts to work simultaneously on multiple manufacturing projects such as iPSC generation, gene editing, differentiation, and cell bank manufacturing for safe and efficacious therapeutic products.

ASC estimates it will be able to take on four times as many projects once the expansion is complete early next year. Work on construction will begin within the next month and the company has already started the process to hire new staff.

President and CEO, Dr. Ruby Yanru Chen-Tsai, Ph.D. said, We are committed to becoming a CDMO leader to support regenerative medicine and cell/gene therapy development and manufacturing. We aim to expand our bio-manufacturing capacity to meet the fast-growing demand in the cell and gene therapy industry.

"Our unique platform of GMP-grade allogeneic iPSC and TARGATTgene editing technology provides our partners great advantages, including shorter manufacturing timelines, non-viral gene editing, and genomic stability and safety.

ASC has a Drug Manufacturing License from the California Department of Public Health, Food and Drug Branch (FDB). It has a Quality Management System (ISO 13485 certified) and established cGMP-compliant protocols for cell banking and manufacturing, iPSC generation, genome editing, iPSC differentiation, and cell product manufacturing.

With over 13 years of gene-editing and stem cell expertise, ASC offers customized cell and gene CRO/CDMO solutions. Its core iPSC and genome editing (CRISPR and TARGATT) technologies, facilitate site-specific, large cargo (up to 20kb) transgene integration and the development of allogenic cell products.

See more here:
Applied StemCell expands manufacturing facility to support cell and gene therapies - BioPharma-Reporter.com

Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic…

Study population

A total of 202 patients with FLT3-ITD AML (sorafenib, n=100; control, n=102) were recruited from June 20, 2015, to July 21, 2018. The median age was 35 (range: 1860) years, with 102 males and 100 females. Patient characteristics are summarized in Table 1. Baseline factors were well balanced between the two groups. With a median of 18 days after sorafenib initiation, 59 of 100 patients required dose modifications due to adverse events, including 42 dose reductions, 12 dose interruptions, and 5 discontinuations. The median follow-up was 36.8 (range, 2.567.1) months post-transplantation.

EBV-DNAemia occurred in 22 (22.0%) patients in the sorafenib group and 23 (22.5%) patients in the control group (P=0.925). Four patients developed EBV-DNAemia 1 year after allo-HSCT, including two in the sorafenib group and two in the control group. The 1-year cumulative incidence of EBV-DNAemia was 22.0% (95% CI: 14.430.6%) and 22.5% (15.031.1%) in the sorafenib and control groups (HR=0.946, 95% CI: 0.5271.698, P=0.931). The 3-year cumulative incidence of EBV-DNAemia was 24.0% (16.132.8%) and 24.5% (16.633.2%) in the two groups, respectively (HR=0.930, 95% CI: 0.5311.629, P=0.937) (Fig. 2A).

Cumulative incidences of EBV-DNAemia (A), EBV-associated disease (B), CMV-DNAemia (C), and CMV-associated disease (D) in the sorafenib and control groups

Five patients developed EBV-associated diseases in the sorafenib group including 4 EBV-post-transplant lymphoproliferative diseases (PTLD) and 1 EBV-pneumonia, and 6 patients in the control group including 3 EBV-PTLD, 2 EBV-enteritis, and 1 EBV-encephalitis. Two patients developed EBV-associated diseases 1 year after allo-HSCT, including one in the sorafenib group and one in the control group. The 1-year cumulative incidence of EBV-associated diseases was 4.0% (95% CI: 1.39.2%) and 4.9% (1.810.4%) in the sorafenib and control groups (HR=0.745, 95% CI: 0.2002.779, P=0.744). The 3-year cumulative incidence of EBV-associated diseases was 5.0% (1.810.6%) and 5.9% (2.411.6%) in the two groups, respectively (HR=0.745, 95% CI: 0.2272.448, P=0.771) (Fig. 2B).

Only one patient in the control group received EBV-CTL for EBV-PTLD, and none of the patients received DLI for EBV infections. No patients in the sorafenib group died of EBV-associated diseases, and one patient in the control group died of EBV-PTLD. The 3-year cumulative mortality of EBV-associated diseases was 0.0% (95% CI: 0.00.0%) and 1.0% (0.14.8%) in the sorafenib and control groups (HR=0.016, 95% CI: 0.0150458.5, P=0.322).

CMV-DNAemia occurred in 54 (54.0%) patients in the sorafenib group and 53 (52.0%) patients in the control group (P=0.772). Seven patients developed CMV-DNAemia 100 days after allo-HSCT, including four in the sorafenib group and three in the control group. The initial and maximum CMV loads in the sorafenib group were 2070 (range, 51233,600) copies/ml and 2750 (range, 550175,000) copies/ml, compared with 1790 (range, 55012,300) copies/ml and 3120 (range, 57070,500) copies/ml in the control group (P=0.612; P=0.882). The duration of CMV-DNAemia was 16 (range, 450) days and 17 (range, 477) days in the sorafenib and control groups (P=0.904). The 1-year cumulative incidence of CMV-DNAemia was 54.0% (95% CI: 43.763.2%) and 52.0% (41.861.2%) in the sorafenib and control groups (HR=0.974, 95% CI: 0.6671.423, P=0.911). The 3-year cumulative incidence of CMV-DNAemia was 56.0% (45.665.1%) and 52.9% (42.762.1%) in the two groups, respectively (HR=0.991, 95% CI: 0.6821.441, P=0.997) (Fig. 2C).

Up to the last follow-up, 8 patients developed CMV-associated diseases in the sorafenib group including 4 CMV-pneumonia, 3 CMV-enteritis, and 1 CMV-retinitis, and 9 patients in the control group including 6 CMV-enteritis, 2 CMV-pneumonia, and 1 CMV-encephalitis. Six patients developed CMV-associated diseases 100 days after allo-HSCT, including three in the sorafenib group and three in the control group. The 1-year cumulative incidence of CMV-associated diseases was 8.0% (95% CI: 3.714.4%) and 7.8% (3.714.1%) in the sorafenib and control groups (HR=0.949, 95% CI: 0.3562.531, P=0.984). The 3-year cumulative incidence of CMV-associated diseases was 8.0% (3.714.4%) and 8.8% (4.315.3%) in the two groups, respectively (HR=0.830, 95% CI: 0.3202.155, P=0.826) (Fig. 2D).

Seven patients (four in the sorafenib group and three in the control group) received CMV-CTL for CMV infections, and none of the patients received DLI for CMV infections. Two patients in the sorafenib group and two in the control group died of CMV-associated diseases. The 3-year cumulative mortality of CMV-associated diseases was 2.0% (95% CI: 0.46.4%) and 2.0% (0.46.3%) in the sorafenib and control groups (HR=0.955, 95% CI: 0.1346.786, P=0.980).

Univariable and multivariable analyses of the risk factors for EBV and CMV infections post-transplantation are shown in Tables 2 and 3. All patients undergoing HID/MUD transplants received ATG as GVHD prophylaxis, and none of patients undergoing MSD transplants received ATG as GVHD prophylaxis. Considering there was collinearity between transplant modality (HID/MUD vs MSD) and ATG use in the conditioning (ATG vs no ATG), we only included ATG use in the analysis of risk factors for EBV/CMV infections. On multivariate analysis, ATG use was the only risk factor for EBV-DNAemia (HR=4.408, 95% CI: 1.9679.878, P<0.001) and EBV-associated diseases (HR =3.235, 95% CI: 1.0789.711, P=0.036), respectively. ATG use (HR =2.797, 95% CI: 1.7834.387, P<0.001) and aGVHD (HR =1.641, 95% CI: 1.0672.522, P=0.024) were the risk factors for CMV-DNAemia; aGVHD (HR =3.179, 95% CI: 1.1758.601, P=0.023) was the only risk factor for CMV-associated diseases. In contrast, age, sex, EBV and CMV serological status, CR status at transplantation, sorafenib use pre-transplantation and post-transplantation, and cGVHD did not show any significant influence on the risk of EBV and CMV infections.

Immune reconstitution was similar with respect to the counts of T lymphocyte subsets (CD3+, CD3+CD4+, CD3+CD8+), B lymphocytes (CD19+), and NK cells (CD3-CD56+) at 1, 3, 6, 9, and 12 months after allo-HSCT between the sorafenib and control groups (all P >0.05) (Table 4).

At the date of statistical analysis, 142 patients survived and 60 died, of whom 21 were in the sorafenib group and 39 were in the control group. Causes of death were leukemia relapse (n=31; 7 in the sorafenib group and 24 in the control group), infections (n=18; 10 in the sorafenib group and 8 in the control group), GVHD (n=8; 3 in the sorafenib group and 5 in the control group), EBV-PTLD (n=1; control group), thrombotic microangiopathy (n=1; control group), and acute left heart failure (n=1; sorafenib group). The 3-year cumulative incidence of relapse was 13.0% (95% CI: 7.320.4%) and 34.8% (25.544.2%) in the sorafenib and control groups, respectively (HR=0.306, 95% CI: 0.1620.579, P<0.001) (Fig. 3A). The 3-year NRM was 11.1% (95% CI: 5.918.3%) and 12.7% (7.120.0%) in the two groups (HR=0.689, 95% CI: 0.3081.540, P=0.656) (Fig. 3B). The 3-year OS was 79.0% (95% CI: 69.685.8%) and 61.4% (51.170.1%; HR=0.481, 95% CI: 0.2830.818, P=0.005), LFS was 75.9% (95% CI: 66.283.1%) and 52.5% (42.261.7%; HR=0.410, 95% CI: 0.2510.670, P<0.001), and GRFS was 65.8% (95% CI: 55.674.3%) and 46.6% (36.656.0%; HR=0.531, 95% CI: 0.3450.816, P=0.003), respectively, in the sorafenib and control groups (Fig. 3CE).

Cumulative incidences of leukemia relapse (A), non-relapse mortality (B), overall survival (C), leukemia-free survival (D), and GVHD-free/relapse-free survival (E) in the sorafenib and control groups. *P < 0.05

See the original post:
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic...

This Week at FDA: ACIP signs off on bivalent boosters – Regulatory Focus

| 02 September 2022 | By Michael Mezher Welcome to another installment of This Week at FDA, your weekly source for updates big and small on FDA, drug and medical device regulation, and what were reading from around the web. The biggest news out of FDA this week was the agencys decision to authorize bivalent COVID-19 vaccine boosters from Pfizer-BioNTech and Moderna. On Thursday, a key Centers for Disease Control and Prevention (CDC) panel voted 13-1 in support of both modified boosters. On Wednesday, FDA amended the emergency use authorizations (EUAs) for both the Pfizer and Moderna vaccines to authorize the vaccine makers new bivalent compositions targeting the Omicron BA.4/5 subvariants and the original SARS-CoV-2 strain. The bivalent Pfizer-BioNTech booster is authorized for use in individuals 12 and older, while Modernas bivalent shot is authorized for adults 18 and older. FDA noted that the primary series will retain the original monovalent formula, though the monovalent boosters will no longer be offered to the age groups eligible for the bivalent vaccines. The following day, the CDCs Advisory Committee on Immunization Practices (ACIP) voted nearly unanimously to recommend the modified boosters, Stat reports. The updated COVID-19 boosters are formulated to better protect against the most recently circulating COVID-19 variant. They can help restore protection that has waned since previous vaccination and were designed to provide broader protection against newer variants, said CDC Director Rochelle Walensky. She noted that the agency expects to recommend bivalent boosters for other pediatric age groups in the coming weeks. Pfizer has said it plans to submit a request for its Omicron-adapted bivalent vaccine for the 5-11 age group early next month. In other regulatory news, Bloomberg Law reports that FDAs proposed rule to harmonize its regulations on human subject protection and institutional review boards with the Federal Policy for the Protection of Human Subjects, also known as the Common Rule, has gone through Office of Management and Budget (OMB) review, clearing the proposal for publication. We also learned from Endpoints and the Los Angeles Times that a federal judge in California ruled against FDA in its case against the California Stem Cell Treatment Center (CSCTC). The ruling could upend FDAs efforts to reign in stem cell clinics offering unproven treatments. FDA ended a multi-year period of enforcement discretion for regenerative medicine products last year and has since stepped up efforts to bring such entities in compliance with its regulations. It has written dozens of untitled letters to companies offering various cellular-derived products that the agency feels should be subject to a biologics license application. Drugs & Biologics On Thursday, FDA announced a new pre-consortium partnership with the Critical Path Institute (C-Path) aimed at facilitating the development of drugs for patients with lysosomal diseases. The partnership will involve academic institutions, drugmakers and patient groups, and the effort falls under FDAs Accelerating Rare disease Cures (ARC) program. FDA also announced the approval of Sanofis Xenpozyme (olipudase alfa) as the first approved treatment for acid sphingomyelinase deficiency (ASMD) in the US. ASMD has a debilitating effect on peoples lives and there is a critical need to increase treatment options for patients who suffer from this rare disease, said Christine Nguyen, director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDAs Center for Drug Evaluation and Research. The drug is an enzyme replacement therapy that reduces the amount of sphingomyelin accumulation in the liver, spleen and lungs. It received fast track, breakthrough therapy, priority review and orphan designation, and FDA awarded the company a valuable rare pediatric disease priority review voucher with the approval. Additionally, the agency posted new data on the impact of its Generic Drug User Fee Amendments (GDUFA II) science and research efforts in FY2021.

For generic products in development, FDA noted that the number of pre-ANDA meetings impacted by the agencys research increased from 92 meetings in FY2020 to 113 meetings in FY2021. Similarly, the number of controlled correspondences impacted by its research rose from 291 to 457 in the same time period. Some measures decreased; FDA said the number of product-specific guidances (PSGs) impacted by its research declined from 86 in FY2020 to 40 in FY2021. For products with an ANDA submission, most of the metrics declined or stayed about the same from FY2020 to FY2021. Medtech This week, the Center for Devices and Radiological Health identified several recalls as Class I recalls, the most serious type, including recalls for Integras CereLink ICP Monitor, certain Philips Respironics BiPAP Machines, Intera Oncologys Intera 3000 Hepatic Artery Infusion Pump and Hamilton Medical AGs Hamilton-C6 Intensive Care Ventilator. We also learned this week that a Philips Respironics will pay $24 million to address alleged false claims for its respiratory products, according to Reuters.

Follow this link:
This Week at FDA: ACIP signs off on bivalent boosters - Regulatory Focus

Recombinant Cell Culture Supplements Market to Witness a CAGR of 12.5% during Forecast Period | BlueWeave Consulting – GlobeNewswire

New Delhi, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Global Recombinant Cell Culture Supplements Market is growing at a high CAGR because of the rising investments in life sciences research and development. The increased preference and use of animal-free supplements is also driving the global recombinant cell culture supplements market.

A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Recombinant Cell Culture Supplements Market was worth USD 309.3 million in the year 2021. The market is projected to grow at a CAGR of 12.5%, earning revenues of around USD 702.5 million by 2028. The global recombinant cell culture supplements market is booming because of the increasing investment in drug research and development coupled with the rising demand for cell culture supplements. Moreover, the advantages of animal-free biotherapeutics and biopharmaceuticals over traditional animal-derived supplements are driving the growth of the global recombinant cell culture supplements market during the forecast period 2022-2028.

Rising Demand for Recombinant Cell Culture Supplements to Drive the Market Growth

Over the years, the demand for recombinant cell culture supplements has risen. This is because cell culture is an integral part of drug research and development, and manufacturing. With the increasing population, humanity is seeing the advent of novel viruses, fungi, and bacteria, causing diseases. To save humanity against acute and chronic, infectious and non-infectious, communicable and non-communicable diseases, it is essential to invent and produce a variety of recombinant proteins, vaccines, diagnostic reagents, advanced therapies, and biotherapeutics and biopharmaceuticals. They are produced using prokaryotic (bacteria, yeast cells) and eukaryotic (mammalian cells, transgenic plants) expression host systems in large-scale settings. These therapeutic and prophylactic recombinant proteins are produced by continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, etc., to achieve high quality and quantity of proteins. The increased production to fulfill the high demand is expected to bolster the growth of the market in the forecast period.

Request for Sample Report @ https://www.blueweaveconsulting.com/report/recombinant-cell-culture-supplements-market/report-sample

Global Recombinant Cell Culture Supplements Market - By Product

Based on products, the global recombinant cell culture supplements market is segmented into recombinant growth factors, recombinant insulin, recombinant albumin, recombinant transferrin, recombinant trypsin, recombinant aprotinin, recombinant lysozyme, and others. Amidst the segmentation, the recombinant albumin (rAlbumin) segment is expected to grow with the highest CAGR during the forecast period 2022-2028 because albumin is a widely used nutrient in all cells cultures; for example, the production of monoclonal antibodies.

Global Recombinant Cell Culture Supplements Market - Regional Insights

Based on regions, the global recombinant cell culture supplements market has been segmented into five categories- North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Amidst the segmentation, North America dominated the global Recombinant Cell Culture Supplements market share in 2021 due to the availability of appropriate technology and sufficient funding. On the other hand, Europe is estimated to grow at the highest rate due to a large number of recombinant cell culture supplement products and manufacturing units, biopharmaceutical organizations and research institutes, and increased government funds for cell science research organizations.

Please Visit the Press Release: https://www.blueweaveconsulting.com/press-release/global-recombinant-cell-culture-supplements-market-to-witness-a-cagr-of-12-5-during-forecast-period

Impact of COVID-19 on Global Recombinant Cell Culture Supplements Market

As a result of the COVID-19 pandemic, worldwide lockdowns were imposed, and manufacturing and operations were seriously affected. This hampered the ongoing research and clinical development of various biopharmaceutical products. To prevent infection from the notorious SARS-CoV-2, research grants were given out for the research and development of Covid vaccines. In the later phases of the pandemic, the governments emphasis shifted on building a robust supply chain for the transportation of Covid test kits, diagnostics, drugs, vaccines, and recombinant supplements. Due to the recommencement of sales for research purposes, the recombinant cell culture supplement-producing firms were able to maintain their financial position.

Competitive Landscape

Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Hi-Media Laboratories, Sartorius AG, InVitro, SeraCare Life Sciences Inc., GE Healthcare, Novozymes A/S, Advanced Biotechnologies Inc., Lonza, STEMCELL Technologies Inc., PeproTech Inc., Sino Biological Inc., FUJIFILM Irvine Scientific, Evercyte GmbH, Kingfisher Biotech Inc. In March 2022, Thermo Fisher Scientific acquired PeproTech, a company that specializes in the development and manufacturing of recombinant proteins, for USD 1.85 billion. The companies aim to expand their business by setting up more manufacturing plants to gain a significant market share. For example, in May 2022, FUJIFILM Irvine Scientific built a new bioprocessing center in China. They also constructed a new cell culture media manufacturing facility in the Netherlands in June 2019.

Dont miss the business opportunity in the Global Recombinant Cell Culture Supplements Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the global recombinant cell culture supplements market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the global recombinant cell culture supplements market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Recent Development

Scope of the Report

By Products

By Application

By Expression System

By Region

Please Find Below Some Related Reports:

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing both qualitative and quantitative data to boost the performance of your business solutions. BWC has built its reputation from the scratch by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Contact Us:

BlueWeave Consulting & Research Pvt. Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

info@blueweaveconsulting.com https://www.blueweaveconsulting.com/

https://www.linkedin.com/company/blueweaveconsulting/

Originally posted here:
Recombinant Cell Culture Supplements Market to Witness a CAGR of 12.5% during Forecast Period | BlueWeave Consulting - GlobeNewswire

The amniotic products market is expected to grow from US$ – GlobeNewswire

New York, July 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Amniotic Products Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, End User, and Geography" - https://www.reportlinker.com/p06295644/?utm_source=GNW The amniotic membrane and suspension are two products that can be used for treatment.

The amniotic membrane is the innermost layer of the placenta that nourishes and maintains an unborn child. Amniotic fluid is the liquid that surrounds the baby until delivery. Due to the high prevalence of burn wounds, demand for wound care biologics, such as amniotic membranes, has increased significantly.According to the WHO, many burn cases occur in low- and middle-income countries, with over 2-3rd occurring in the WHO African and Southeast Asian areas.

Every year, one million people in India suffer from mild to severe burns (Source: WHO).Other Southeast Asian countries, such as Bangladesh and Nepal, have a high rate of burn cases.

An estimated 173,000 children in Bangladesh yearly suffer from moderate to severe burns. Burn is Nepals second most prevalent injury, accounting for 5% of disability cases. Based on type, the amniotic products market has been bifurcated into amniotic membranes and amniotic suspensions.The amniotic membranes segment is likely to hold the largest share of the market in 2022.

The amniotic membrane segment growth is growing due to increasing research in stem cell and regenerative medicine, high R&D investments, and an increase in the number of surgeries conducted globally.Further, they are commonly employed in the treatment of bacterial keratitis, corneal ulcers, cataract, glaucoma, bullous keratopathy, corneal degeneration, ocular dystrophy, eyelid reconstruction, and other eye surface problems.

The expansion in the worlds senior population increases the number of ophthalmology surgeries, , resulting in a growing need for tissue-based products.Further, PalinGen, Fl?Graft, AmbioDisk, and AmnioFix are examples of commercially available dehydrated amniotic membranes.

In addition, these membranes are widely used in the treatment and management of surgical wounds and incisions, owing to properties such as their ability to maintain a watertight seal, inhibit inflammatory responses, and prevent disease transmissions. Hence, these factors are driving the segment growth. In December 2016, the US passed the 21st Century Cures Act.This new law was passed with the goal of advancing regenerative medicine research and medical innovation.

The Act contains a number of provisions that could impact the development and approval of many products in the coming years.A new "Regenerative Medicine Advanced Therapy" classification and a fast-track approval procedure for innovative regenerative medicine products and therapies have been developed due to this Act.

The passage of this Act could lead to the approval of new regenerative medicine products and therapies in the US and a boost in regenerative medicine research and development.It was designed to promote patient access to electronic health information, advance innovation, and address information blocking practices.

The 21st Century Cures Act was created to help speed up medication development and approval processes, allowing for faster and more efficient delivery of new medical advancements to patients. These requirements are expected to improve interoperability and facilitate electronic health information access, exchange, and use. A few key primary and secondary sources referred to while preparing the report on the prostate cancer nuclear medicine diagnostics market are the World Health Organization (WHO), the Centers for Disease Control and Prevention, and the National Programme for Prevention, Management and Rehabilitation of Burn Injuries. Read the full report: https://www.reportlinker.com/p06295644/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post:
The amniotic products market is expected to grow from US$ - GlobeNewswire

University of Minnesota scientist responds to fraud allegations in Alzheimer’s research – Star Tribune

A senior University of Minnesota scientist said it is "devastating" that a colleague might have doctored images to prop up research, but she defended the authenticity of her groundbreaking work on the origins of Alzheimer's disease.

Dr. Karen Ashe declined to comment about a U investigation into the veracity of studies led by Sylvain Lesn, a neuroscientist she hired and a rising star in the field of Alzheimer's research. However, she criticized an article in Science magazine that raised concerns this week about Lesn, because she said it confused and exaggerated the effect the U's work had on downstream drug development to treat Alzheimer's-related dementia.

"Having worked for decades to understand the cause of Alzheimer disease, so that better treatments can be found for patients, it is devastating to discover that a co-worker may have misled me and the scientific community through the doctoring of images," Ashe said in an e-mail Friday morning. "It is, however, additionally distressing to find that a major scientific journal has flagrantly misrepresented the implications of my work."

Questions have surfaced about as many as 10 papers written by Lesn, and often coauthored by Ashe and other U scientists, and whether they used manipulated or duplicated images to inflate the role of a protein in the onset of Alzheimer's.

The Science article detailed efforts by Dr. Matthew Schrag, an Alzheimer's researcher in Tennessee, who colorized and magnified images from Lesn's studies in ways that revealed questions about whether they were doctored or copied. Expert consultants agreed in the article that some of the images in the U studies appeared manipulated in ways that elevated the importance of a protein called A*56.

Many of the images were of Western blot tests showing that A*56, also called amyloid beta star 56, was more prevalent in mice that were older and showed signs of memory loss.

The U studies have been so influential on the course of Alzheimer's research over the past two decades that any evidence of manipulation or false study results could fundamentally shift thinking on the causes of the disease and dementia. The investigation also implicates two successful researchers on a key measure by which they are judged: their ability to pull in federal grants.

Lesn was a named recipient of $774,000 in National Institutes of Health grants specifically involving A*56 from 2008 through 2012. He subsequently received more than $7 million in additional NIH grants related to the origins of Alzheimer's.

Lesn, who did not reply to an e-mail asking for comment, came to the U in 2002 as a postdoctoral research associate after earning his doctorate at the University of Caen Normandy. He took charge of his own U lab by 2009 and became associate director of graduate studies in the neuroscience program in 2020. He was the first- or last-named author on all of the disputed studies, meaning he either instigated the research or was the senior scientist overseeing the work.

Ashe said there are two classes of A proteins, which she refers to as Abeta, and that her efforts have focused on one while drugmakers have unsuccessfully targeted the other with potential Alzheimer's treatments. As a result, she said it was unfair of the Science article even as it raised concerns about research improprieties to pin an entire industry's lack of progress on the scrutinized U research.

"It is this latter form that drug developers have repeatedly but unsuccessfully targeted," she said. "There have been no clinical trials targeting the type 1 form of Abeta, the form which my research has suggested is more relevant to dementia. [The article] has erroneously conflated the two forms of Abeta."

The scientific journal Nature is reviewing a 2006 study led by Lesn regarding the existence and role of A*56 and urging people to use it cautiously for now. Concerns emerged in part because researchers at other institutions struggled to replicate the results.

Two other 2012 and 2013 papers were corrected earlier this year, with U researchers acknowledging errant images but stating that they didn't affect the overall conclusions. However, Schrag said he has concerns the corrected images also were manipulated.

"I think those corrected images are quite problematic," he said.

Beneath the research controversy is a fundamental search and debate over the causes of Alzheimer's and related dementia. One theory is that certain Abeta proteins result in the development of amyloid plaques, which clog up space between nerve cells in the brain and inhibit memory and cognition. Another is that tau proteins clump inside the brain's thinking cells and disrupt them.

Ashe's research has explored both possibilities. Since 1986, she has been a named recipient of more than $28 million in NIH grants, making her one of the most productive researchers in U history.

Complicated legacy

Despite a remarkable history of life-saving inventions and surgical accomplishments, the U also has a legacy of research stars being implicated in scandals.

The late Dr. S. Charles Schulz stepped down as U psychiatry chair in 2015 amid claims by a grieving family that their son, who died by suicide, was coercively recruited into a schizophrenia drug trial.

Duplicated images and errors forced the correction of a 2002 Nature study, led by Dr. Catherine Verfaillie, claiming that certain adult stem cells possessed flexible abilities to grow and develop other cell types.

The late Dr. John Najarian was a pioneer in organ transplantation who elevated the U's global profile, but he faced federal sanctions in the 1990s related to illicit sales of an experimental anti-rejection medication that improved transplant outcomes.

A U investigation of Lesn's work will follow its standard policy of research misconduct allegations, according to a statement from the medical school.

Originally posted here:
University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune

Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans – VegNews

Cell-cultured seafood startup Pearlita Foods has successfully created the worlds first plant-based oyster prototype that looks and tastes just like a traditional oyster. The prototype is made using plant-based and cell-based technologies with a proprietary mushroom and seaweed base as well as Pearlitas novel flavor mixture that gives the oyster a pure, delicate, and authentic ocean taste and texture. The startup also plans to create biodegradable oyster shells that will impart the same experience as traditional oysters but remove the need for shucking, making it easier for consumers to serve and eat.

Earlier this year, Pearlita embarked on producing an alternative to oysters in an effort to meet the demand for ocean-derived delicacies using plant-based and cell-based technologies without harming the oceans. The startup will begin by rolling out its hybrid product while it continues to develop its cell lines for a line of fully cultured oysters. To cultivate oysters, Pearlita isolates cells from an oyster tissue sample, and with it, the startup is able to produce thousands of cultivated oysters.

While the startup continues its research and development on cultured oysters and biodegradable shells, Pearlita will debut its hybrid plant-based oyster using recycled oyster shells for its showcasing and tastings. In North Carolina, where Pearlita is headquartered, many coastal communities offer shell recycling drop-off locations to build new oyster reefs instead of disposing of the shells in landfills.

Pearlita Foods

According to Pearlita, over 85 percent of wild oyster reefs have been lost globally due to overfishing. Pearlita wants to change the seafood industry and it is striving to make cultivated oysters and other cell-based seafood commonplace so that traditional oysters can remain in the oceans and contribute to healthy ecosystems. Additionally, according to government advisories from the Centers for Disease Control and Prevention, ocean-derived bivalve shellfish such as clams, geoducks, mussels, scallops, and oysters can transmit norovirus to the people who eat them. These illness outbreaks are most often linked to oysters and can be deadly.

The startup aims to produce oysters with no reliance on the ocean or live animals, by using stem cells and bioreactors to produce cell-based oysters that are rich in flavor and nutrition. And because they are produced in a sterile environment, cultivated seafood is devoid of bacteria and virus contamination. Going forward, Pearlita plans to develop squid and scallop prototypes as well and work on scaling up production.

The cellular aquaculture startup recently secured investment from investment firm CULT Food Science to help scale its prototype. We are impressed by and proud of Pearlitas successful production of its first cultivated oyster prototype. Pearlitas commitment to making the world a better place and doing its part to increasing the worlds food security is encouraging as we possess the same goals, Lejjy Gafour, Chief Executive Officer of CULT, said in a statement. Pearlita is taking great steps to advance the production of cultured seafood on a mass scale. We are energized by the positive contributions that their team is making to the cellular agriculture industry.

Finless Foods

While Pearlita is focusing on developing ethical and sustainable seafood alternatives to ocean delicacies such as oysters, other food technology companies are tackling fish species such as tunawhich is the most consumed fish in the United States. Finless Foods is taking a similar approach to Pearlita by using plants and cultivated cells to make sustainable seafood, starting with tuna which will be available to restaurants and foodservice channels this year.

Earlier this year, Finless Foods showcased its plant-based tuna as part of a poke bowl and tacos served to guests at the Food Network & Cooking Channel South Beach Wine & Food Festival in Miami. The product is made from a blend of nine proprietary, plant-based ingredients that together mimic the texture and taste of sushi-grade tuna while also being able to withstand the addition of citrus and marinades.

Tuna plays an important role in ocean health and has historically been a difficult species for aquaculture, Finless Foods co-founder Brian Wyrwas said in a statement. We felt that developing viable alternatives would yield the greatest net impact for our ocean.

Other competitors in the cellular aquaculture space include San Diego-based BlueNalu, which is working to develop cell-based alternatives to fish, including yellowtail amberjack which it sampled in a private-tasting in 2019. In San Francisco, cellular aquaculture startup Wild Type is also working on growing sushi-grade meat made from a small amount of fish cells. Its pilot facility became operational in 2021 and Wild Type hopes to open an adjacent tasting restaurant where its cultivated fish can be showcased in traditional (but more sustainable) sushi preparations.

Over in Singapore, the countrys first cell-based seafood startup, Shiok Meats, is creating cultivated crab and lobster. Currently, Singapore is the only country in the world that allows the sale of cultivated meat. There, cultivated chicken made by GOOD Meat (a subsidiary of Eat Just) was approved for sale in December 2020.

For the latest vegan news, read: Chipotle Invested a $150 Million Funding Round For Vegan Steak StartupNavy Will Test Vegan Meat on at Least 2 US BasesCountry Crocks First Whipping Cream Is Made From Lentil Milk

Nicole Axworthy is the News Editor at VegNews and author of the cookbook DIY Vegan.

Happy birthday, VegNews! To celebrate, we're having a mega subscription salecomplete with incredible vegan prizes.

CHECK IT OUT

Happy birthday, VegNews! To celebrate, we're having a mega subscription salecomplete with incredible vegan prizes.

CHECK IT OUT

Read more:
Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans - VegNews

Global Virus Filtration Market To Be Driven By The Increasing Incidence Of Chronic Diseases In The Forecast Period Of 2021-2026 This Is Ardee – This…

The new report by Expert Market Research titled, GlobalVirus Filtration MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global virus filtration market, assessing the market based on its segments like product, applications, end-use, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://bityl.co/CQEk

The key highlights of the report include:

Market Overview (2016-2026)

One of the major factors driving to the virus filtration is the rising prevalence of chronic diseases. The increasing number ofchronicdiseases such ascancer,diabetes, and autoimmune disorders is expected to drivebiologicsdemand. The major driver, which is anticipated to increase the market growth during the forecast period, is the compliance of the product with drug development and manufacturing regulatory frameworks such as the Current Good Manufacturing Practice (cGMP) legislation. The increased focus on vaccines,proteintreatments, blood products, cellular therapy products, gene therapy products, tissue products, and stem cell products is likely to stimulate demand for consumables such as reagents, kits, and membranes. Increased demand for outsourcing services that cater to the specialised demands of vaccine and therapeutic protein manufacturing companies has come from a surge in the number of vaccine and therapeutic protein manufacturing companies, providing lucrative growth potential for the industry.

Industry Definition and Major Segments

Viruses are characterised as unwanted tiny contagious agents or particles that must be eradicated in order to prevent drug infertility, especially in the pharmaceutical sector. Virus filtration membranes are used to remove viruses from biopharmaceutical products during purification. It is a critical practice in the pharmaceutical sector because it ensures the purity and consistent consumption of vital products while also optimising the economic process and reducing waste. Virus filtering is usually done at the end of any process purification stage.

Explore the full report with the table of contents@https://bityl.co/CQEl

By product, the market includes:

The end use of the industry is divided into:

The leading application of the industry includes:

On the basis of region, the industry is divided into:

Market Trends

The demand for medicinal biologics is increasing, which drives up the demand for virus filtration products in research and development and manufacturing. CROs are cooperating with biotechnology and biopharmaceutical businesses to create new medications and therapies, which is projected to drive the market expansion. The increased usage of these products for virus filtration provides lucrative growth opportunities to the market. Product advancements and new product launches support vendors in maintaining their dominance in the market, which is anticipated to boost the market growth. The presence of big biopharmaceutical and biotechnology companies, well-developed healthcare infrastructure, and access to advanced products are some of the major factors contributing to growth of the marker. The increasing adoption of single-use technologies, coupled with rapid technological advancement, is anticipated to propel the market growth during the forecast period.

Key Market Players

The major players in the market are Merck Group, Asahi Kasei Corporation, Sartorius Group, General Electric, Danaher Corporation, Pendotech, Lonza Group, and Charles River Laboratories, Inc, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact

Company Name: Claight Corporation Contact Person: Steven Luke, Corporate Sales Specialist U.S.A. Email:sales@expertmarketresearch.com Toll Free Number: +1-415-325-5166 | +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA Website:https://www.expertmarketresearch.com

Read More Reports:

Retinitis Pigmentosa Treatment Market: https://freighteurasia.com/global-retinitis-pigmentosa-treatment-market-to-be-driven-by-growth-of-the-retinal-disorder-treatment-market-in-the-forecast-period-of-2021-2026/

Aerospace Coatings Market: https://freighteurasia.com/global-aerospace-coatings-market-to-be-driven-by-the-rapid-aircraft-production-in-the-forecast-period-of-2021-2026/

POS Machines Market: https://freighteurasia.com/global-pos-machines-market-to-be-driven-by-the-growth-of-the-payments-industry-and-the-increasing-iot-penetration-in-the-forecast-period-of-2021-2026/

Australia Lime Market: https://freighteurasia.com/australia-lime-market-to-be-driven-by-the-growing-construction-industry-in-the-forecast-period-of-2021-2026/

Krypton Gas Market: https://freighteurasia.com/global-krypton-gas-market-to-be-driven-by-the-rising-demand-for-oxygen-in-the-wake-of-the-covid-19-outbreak-as-number-of-patients-requiring-ventilators-are-rising-in-the-forecast-period-of-2021-2026/

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Visit link:
Global Virus Filtration Market To Be Driven By The Increasing Incidence Of Chronic Diseases In The Forecast Period Of 2021-2026 This Is Ardee - This...